Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of Circulating Tumor DNA Dynamics for Treatment Optimization in Stage II-III HER2-Positive and Triple-Negative Breast Cancer Candidate to NAT

NCT07662252 is registered in ClinicalTrials.gov with Federico II University as lead sponsor.

NCT NCT07662252
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07662252 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of Circulating Tumor DNA Dynamics for Treatment Optimization in Stage II-III HER2-Positive and Triple-Negative Breast Cancer Candidate to NAT
Lead sponsor
Federico II University
Phase
Observational
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
June 30, 2029
Enrollment
186 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, her2 + breast cancer, triple negative breast cancer (tnbc)